Norbert Bischofberger, a former Gilead executive, has been running Kronos Bio for a little more than a year — and it’s been a year full of changes. The company has a fresh logo, programs inching closer to clinical trials, and more than $100 million of new money from a financing round announced Thursday.
Kronos, which has offices in Cambridge, Mass., and near San Francisco, is hoping to find new small-molecule drugs for cancer using a novel method for screening potential drug targets.
About the Author Reprints
